State Drug Firms Seek Diversification In India
This article was originally published in PharmAsia News
State-run pharmaceutical companies in India seek to take advantage of their large land holdings to diversify into developing commercial complexes in information-technology parks they also run. Bengal Chemicals and Pharmaceuticals is building a large office complex on two acres it owns in Mumbai and plans to lease space while it pursues its drug-development business. Indian Drugs and Pharmaceuticals plans a similar arrangement at the four locations where it will include biotech parks. The state entities still need clearance from a group of government ministers before they can follow through with their diversification plans. (Click here for more
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.